Rothschild & Co Asset Management US’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Rothschild & Co Asset Management US’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-32,498	Closed	-$3.73M	–	362
2014 Q4	$3.73M	Sell	32,498 -38,698	-54%	-$4.69M	0.07%	284
2014 Q3	$11.1M	Sell	71,196 -13,552	-16%	-$1.96M	0.24%	131
2014 Q2	$10.5M	Sell	84,748 -563	-0.7%	-$62.2K	0.21%	151
2014 Q1	$8.84M	Sell	85,311 -4,780	-5%	-$489K	0.2%	185
2013 Q4	$8.1M	Buy	90,091 +1,625	+2%	+$130K	0.18%	206
2013 Q3	$5.92M	Buy	+88,466	New	+$6.1M	0.13%	244

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rothschild & Co Asset Management US's SLXP Position: Q1 2015 in Review

Rothschild & Co Asset Management US sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 32,498 shares — an estimated $3.73M sold.

Rothschild & Co Asset Management US first reported a position in SLXP in Q3 2013 and held it in 6 quarters. The position peaked at $11.1M in Q3 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

Rothschild & Co Asset Management US reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
Rothschild & Co Asset Management US sold 32,498 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $3.73M.
Rothschild & Co Asset Management US first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2013 and held it in 6 quarters.
Rothschild & Co Asset Management US's SALIX PHARMACEUTICALS LTD DEL position peaked at $11.1M in Q3 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on Rothschild & Co Asset Management US's 13F filing for Q1 2015, filed 15 May 2015.